Published Jun 9, 2015
Princeton, NJ, USA, June 9, 2015 – The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held its 20th Annual International Meeting May 16-20, 2015 in Philadelphia. The 2015 Annual International Meeting marked ISPOR’s 20th anniversary and focused on the theme of “Integrating Big Data, Patient Data, and Cost-Effectiveness into Clinical Practice: Promise and Prospects.” More than 3,700 professionals, from research and academia, policy makers, payers, and patient representative groups from the U.S. and around the world, attended. The ISPOR 2015 “Scientific Achievement Awards” were announced on the second day of the meeting on Tuesday, May 19, 2015. The ISPOR Awards Program is designed to foster and recognize excellence and outstanding technical achievement in pharmacoeconomics / health economics and outcomes research. In addition to scientific achievement, ISPOR also awards lifetime achievement and leadership awards to those who advance these disciplines in the field and by service to the Society. Recipients were: *Anthony John (Tony) Culyer, CBE, Hon DEcon, FMedSci, Emeritus Professor of Economics, University of York, UK, Recipient: ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award. Dr. Culyer is Emeritus Professor of economics at York (England); Chair, NICE International Advisory Group, London, England; Senior Fellow at the Institute of Health Policy, Management and Evaluation, University of Toronto; Adjunct Scientist, Institute for Work and Health, Toronto; and Distinguished Visiting Scholar, University of the Witwatersrand, South Africa. He was the founding Organizer of the Health Economists' Study Group and the founding Co-Editor of the Journal of Health Economics. He was founding Vice Chair of the National Institute for Health and Care Excellence (NICE). For many years Dr. Culyer was Chair of the Office of Health Economics in London. He has published widely, mostly in health economics. The third edition of his The Dictionary of Health Economics (Edward Elgar) came out in 2014. (Dr. Culyer will be presented his award at the ISPOR 18th Annual European Congress in Milan, Italy in November 2015). ISPOR’s highest service award, the ISPOR Marilyn Dix Smith Leadership Award, was established in 2014 in honor of ISPOR’s Founding Executive Director, Marilyn Dix Smith, RPh, PhD. The Award recognizes one individual each year that has provided extraordinary leadership to the Society. [caption id="attachment_2072" align="alignleft" width="243"]Zeba MDS Zeba Khan, PhD (l) and Renee Goldberg Arnold, PharmD, RPh[/caption] *Zeba M. Khan, RPh, PhD, Vice President, Celgene Corporation, Summit, NJ, USA, Recipient: Marilyn Dix Smith Leadership Award. Dr. Khan joined Celgene Corporation as Vice President of Global Pricing and Market Access in 2008. She led the development and implementation of pricing, health economics, outcomes research, and market access strategies and policies for all therapeutic areas. In 2012, she established the public policy function and is currently Vice President of Corporate Responsibility. She is recognized for her nearly 20 years of outstanding leadership and dedicated service to ISPOR. She was instrumental in the formation of the ISPOR Student Network, was the first ISPOR Student Network Faculty Advisor since its inception in 2000, and continues to serve in this capacity. She is Chair of the ISPOR Finance Committee. Dr. Khan is currently ISPOR Treasurer on the Board of Directors and is also involved in various Special Interest Groups, Working Groups, and Committees. Her dedication, service, and leadership to ISPOR have been recognized with numerous Distinguished Service awards. She is an adjunct assistant professor at the Ernest Mario School of Pharmacy at Rutgers University. [caption id="attachment_2076" align="alignright" width="243"]Jalpa Doshi, PhD (l) and Anupam B. Jena, MD, PhD Jalpa Doshi, PhD (l) and Anupam B. Jena, MD, PhD[/caption] *Anupam B. Jena, MD, PhD, Assistant Professor of Health Care Policy and Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA, Recipient: Bernie J. O’Brien New Investigator Award. Dr. Jena is an Assistant Professor of health care policy and medicine at Harvard Medical School and an internist at Massachusetts General Hospital. Dr. Jena is also a Faculty Research Fellow at the National Bureau of Economic Research. His research involves several areas of health economics and policy, including the economics of medical innovation and cost-effectiveness, the economics of physician behavior, medical malpractice, and productivity in health care. He graduated Phi Beta Kappa from the Massachusetts Institute of Technology and received his MD and PhD in Economics from the University of Chicago, completing his residency in internal medicine at Massachusetts General Hospital. He is a recipient of the 2007 Eugene Garfield award from Research America for the best paper on the economic impact of medical technology. In 2013, he received the “NIH Director's Early Independence Award,” given to junior scientists who show exceptional promise in biomedical and behavioral science research. [caption id="attachment_2083" align="alignleft" width="270"]Federico Lisa A. Prosser, PhD (l) and Federico Augustovski, MD, MSc, PhD[/caption] *Lisa A. Prosser, PhD, Associate Professor and Interim Director, Child Health Evaluation and Research (CHEAR) Unit, University of Michigan, Ann Arbor, MI, USA, Recipient: Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research. Dr. Prosser is an Associate Professor and Interim Director of the Child Health Evaluation and Research (CHEAR) Unit at the University of Michigan. Her research focuses on measuring the comparative effectiveness and cost-effectiveness of childhood health interventions using methods of decision sciences and economics. Her current research topics include evaluating long-term health and economic outcomes for newborn screening programs using simulation modeling; measuring public values for screening programs; and developing new methods for valuing family spillover effects of childhood illness. Dr. Prosser received her PhD in health policy from Harvard University.  She holds a MS degree from the MIT Sloan School of Management and a MS from the Technology and Policy Program at MIT. [caption id="attachment_2086" align="alignright" width="270"]Greenberg Joshua A. Roth, PhD, MHA (l) and Dan Greenberg, PhD[/caption] *Joshua A. Roth, PhD, MHA, Assistant Member, AHRQ Patient-Centered Outcomes Research K12 Scholar, Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, Recipient: Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research. Dr. Roth is an Assistant Member at the Hutchinson Institute for Cancer Outcomes Research at Fred Hutchinson Cancer Research Center and an Affiliate Assistant Professor in the Pharmaceutical Outcomes Research and Policy Program at the University of Washington. He is an Agency for Healthcare Research and Quality K12 scholar in patient-centered outcomes research. His primary research interest is in the application of comparative effectiveness research methods to inform translation of lung and breast cancer therapeutics and diagnostics, including observational study design, decision modeling, randomized controlled trial design, systematic review, and meta-analysis. His current research focuses on evaluating patient perspectives on lung cancer screening and applying value of information analysis to identify high-value study designs for future lung cancer screening research. Dr. Roth received his PhD in pharmaceutical outcomes research from the University of Washington. He also holds a MHA degree from the department of health services at the University of Washington. *Lucas M.A. Goossens, PhD, Assistant Professor of Quantitative Analysis, Erasmus University, Institute for Health Policy & Management, Rotterdam, The Netherlands, Recipient: Value in Health Paper of the Year Award. Dr. Goossens is an Assistant Professor of Quantitative Analysis at the Institute of Health Policy and Management (iBMG) and the Institute for Medical Technology Assessment (iMTA) of Erasmus University Rotterdam in The Netherlands. His research is centered around economic evaluations in health care and broader epidemiological studies. He has published in health economic, medical, and epidemiological journals on topics such as interventions in pulmonary diseases, patient preferences, hospital-at-home schemes, and medication adherence. He has a special interest in innovative epidemiological considerations and statistical methods in economic evaluations, medical trials and epidemiological studies, including discrete choice experiments. He holds a PhD and MSC in health economics and an MA in History. He currently serves as the Director of the Research Master program of iBMG and The Netherlands Institute for Health Sciences.  (Dr. Goossens will be presented his award at the ISPOR 18th Annual European Congress in Milan, Italy in November 2015) In addition, ISPOR’s Research Presentation Podium and Poster Awards, established in 1998 to recognize the scientific merit of podium and poster presentations of the ISPOR Annual International Meetings, Annual European Congresses, and Asia-Pacific and Latin America Conferences, were also presented on Wednesday, May 20, 2015. This year, over 120 judges evaluated 48 podium presentations and over 100 nominated poster presentations. “We congratulate all of those who received ISPOR 2015 Scientific Achievement Awards,” said ISPOR CEO and Executive Director Nancy Berg. “With these well-deserved awards we are happy to recognize their dedication and hard work, work that helps ISPOR’s efforts to further pharmacoeconomics and outcomes research serving the goal of improving health care as well as making it more cost-effective. We hope that by receiving these awards, the recipients will continue to inspire others and serve as models for those who are currently engaged in important work of the same excellence.”

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now